We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Arcus Biosciences (RCUS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Arcus Biosciences is a member of our Medical group, which includes 899 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RCUS's full-year earnings has moved 8.75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, RCUS has returned 23.96% so far this year. Meanwhile, the Medical sector has returned an average of -21.21% on a year-to-date basis. As we can see, Arcus Biosciences is performing better than its sector in the calendar year.
To break things down more, RCUS belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has lost an average of 19.04% so far this year, meaning that RCUS is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to RCUS as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Arcus Biosciences (RCUS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Arcus Biosciences is a member of our Medical group, which includes 899 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RCUS's full-year earnings has moved 8.75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, RCUS has returned 23.96% so far this year. Meanwhile, the Medical sector has returned an average of -21.21% on a year-to-date basis. As we can see, Arcus Biosciences is performing better than its sector in the calendar year.
To break things down more, RCUS belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has lost an average of 19.04% so far this year, meaning that RCUS is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to RCUS as it looks to continue its solid performance.